세포 및 유전자 치료 바이오 제조 시장 : 제품 유형,단계,용도,최종사용자, 지역별 예측(-2032년)

Global Cell and Gene Therapy Biomanufacturing Market Research Report Information By Product Type (Consumables, Equipment and Software Solutions), By Usage (Commercial Stage Manufacturing and Research Stage Manufacturing), By Application (Upstream Processing, Harvesting and Downstream Processing), By End User (Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations and Cell Banks) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) - Forecast Till 2032

Market Overview

In 2022, the market size of cell and gene therapy biomanufacturing was estimated to be USD 12.6 billion. The Cell and Gene Therapy Biomanufacturing market industry is anticipated to witness a compound annual growth rate (CAGR) of 10.60% from USD 13.9 Billion in 2023 to USD 31.2 Billion by 2032 through the forecast period (2024-2032). The primary market drivers that are fostering market growth are the increasing investments in cell and gene therapy research.

The Cell and Gene Therapy Market is experiencing rapid growth, which is driving the Cell and Gene Therapy Biomanufacturing Market forward by increasing demand for manufacturing solutions. Given the promising clinical trial results and the approval of novel cell and gene therapies, there is a growing necessity to increase production in order to satisfy commercialization requirements. The development of efficient, scalable, and cost-effective biomanufacturing processes and infrastructure is required due to the exponential growth of the market. In response to the increasing demand for cell and gene therapy products, biomanufacturing companies are investing in advanced technologies, including automation, single-use systems, and closed-system bioreactors. Furthermore, the Cell and Gene Therapy Biomanufacturing Market is experiencing growth as a result of the market's expansion, which is fostering collaborations, partnerships, and investments in biomanufacturing capacity to address the swiftly changing cell and gene therapy landscape.

Market segment insights

Consumables, Equipment, and Software Solutions comprise the Cell and Gene Therapy Biomanufacturing Market segmentation, with respect to product type.

Based on usage, the market segmentation comprises Commercial Stage Manufacturing and Research Stage Manufacturing.

Based on application, the market segmentation comprises Upstream Processing, Harvesting, and Downstream Processing.

The Cell and Gene Therapy Biomanufacturing Market segmentation is based on the end user and includes Life Science Companies, Contract Research Organizations, Contract Manufacturing Organizations, and Cell Banks.

Regional Perspectives

The study offers market insights for North America, Europe, Asia-Pacific, and the Rest of the World by region. The Cell and Gene Therapy Biomanufacturing Market has been dominated by North America because of a variety of factors. Initially, the region is home to a thriving ecosystem of pharmaceutical and biotechnology companies that are actively involved in the research and development of cell and gene therapies. Secondly, the market growth is facilitated by the well-established regulatory frameworks and supportive policies for cell and gene therapy manufacturing in North America.

The second-largest market share in the European Cell and Gene Therapy Biomanufacturing market is attributed to the competent workforce. Several factors have contributed to Europe's acquisition of the second-largest market share in the Cell and Gene Therapy Biomanufacturing Market. The region is fortunate to have a skilled personnel, advanced infrastructure, and a well-established biopharmaceutical industry.

The Asia-Pacific Cell and Gene Therapy Biomanufacturing Market is anticipated to experience the most rapid rate of growth from 2024 to 2032. The Cell and Gene Therapy Biomanufacturing Market is experiencing the highest compound annual growth rate (CAGR) in the Asia Pacific region because of diverse factors. Initially, the biopharmaceutical industry in the region is experiencing accelerated growth as a result of the growing investment in research and development, particularly in the fields of cell and gene therapy.

Major Players

Lonza Group, Thermo Fisher Scientific Inc., Merck KGaA, WuXi AppTec, Catalent, Inc., Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Charles River Laboratories, Cytiva, Novasep, and Others are the major players in the Cell and Gene Therapy Biomanufacturing market.

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

• 2.1. DEFINITION
• 2.2. SCOPE OF THE STUDY
  • 2.2.1. RESEARCH OBJECTIVE
  • 2.2.2. ASSUMPTIONS

2.2.3.LIMITATIONS

3. RESEARCH METHODOLOGY

• 3.1. OVERVIEW
• 3.2. DATA MINING
• 3.3. SECONDARY RESEARCH
• 3.4. PRIMARY RESEARCH
  • 3.4.1. PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS

3.4.2.BREAKDOWN OF PRIMARY RESPONDENTS

• 3.5. FORECASTING MODEL
• 3.6. MARKET SIZE ESTIMATION
  • 3.6.1. BOTTOM-UP APPROACH
  • 3.6.2. TOP-DOWN APPROACH
• 3.7. DATA TRIANGULATION
• 3.8. VALIDATION

4. MARKET DYNAMICS

• 4.1. OVERVIEW
• 4.2. DRIVERS
• 4.3. RESTRAINTS
• 4.4. OPPORTUNITIES

5. MARKET FACTOR ANALYSIS

• 5.1. VALUE CHAIN ANALYSIS
• 5.2. PORTER'S FIVE FORCES ANALYSIS
  • 5.2.1. BARGAINING POWER OF SUPPLIERS
  • 5.2.2. BARGAINING POWER OF BUYERS
  • 5.2.3. THREAT OF NEW ENTRANTS
  • 5.2.4. THREAT OF SUBSTITUTES
  • 5.2.5. INTENSITY OF RIVALRY
• 5.3. COVID-19 IMPACT ANALYSIS
  • 5.3.1. MARKET IMPACT ANALYSIS
  • 5.3.2. REGIONAL IMPACT
  • 5.3.3. OPPORTUNITY AND THREAT ANALYSIS

6. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY PRODUCT TYPE

• 6.1. OVERVIEW
• 6.2. CONSUMABLES
• 6.3. EQUIPMENT
• 6.4. SOFTWARE SOLUTIONS

7. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY USAGE

• 7.1. OVERVIEW
• 7.2. COMMERCIAL STAGE MANUFACTURING
• 7.3. RESEARCH STAGE MANUFACTURING

8. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY APPLICATION

• 8.1. OVERVIEW
• 8.2. UPSTREAM PROCESSING
• 8.3. HARVESTING
• 8.4. DOWNSTREAM PROCESSING

9. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY END USER

• 9.1. OVERVIEW
• 9.2. LIFE SCIENCE COMPANIES
• 9.3. CONTRACT RESEARCH ORGANIZATIONS
• 9.4. CONTRACT MANUFACTURING ORGANIZATIONS
• 9.5. CELL BANKS

10. GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET, BY REGION

• 10.1. OVERVIEW
• 10.1. NORTH AMERICA
  • 10.1.1. US
  • 10.1.2. CANADA
• 10.2. EUROPE
  • 10.2.1. GERMANY
  • 10.2.2. FRANCE
  • 10.2.3. UK
  • 10.2.4. ITALY
  • 10.2.5. SPAIN
  • 10.2.6. REST OF EUROPE
• 10.3. ASIA-PACIFIC
  • 10.3.1. CHINA
  • 10.3.2. INDIA
  • 10.3.3. JAPAN
  • 10.3.4. SOUTH KOREA
  • 10.3.5. AUSTRALIA
  • 10.3.6. REST OF ASIA-PACIFIC
• 10.4. REST OF THE WORLD
  • 10.4.1. MIDDLE EAST
  • 10.4.2. AFRICA
  • 10.4.3. LATIN AMERICA

11. COMPETITIVE LANDSCAPE

• 11.1. OVERVIEW
• 11.2. COMPETITIVE ANALYSIS
• 11.3. MARKET SHARE ANALYSIS
• 11.4. MAJOR GROWTH STRATEGY IN THE GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET,
• 11.5. COMPETITIVE BENCHMARKING
• 11.6. LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL CELL AND GENE THERAPY BIOMANUFACTURING MARKET,
• 11.7. KEY DEVELOPMENTS AND GROWTH STRATEGIES
  • 11.7.1. NEW PRODUCT LAUNCH/SERVICE DEPLOYMENT
  • 11.7.2. MERGER & ACQUISITIONS
  • 11.7.3. JOINT VENTURES
• 11.8. MAJOR PLAYERS FINANCIAL MATRIX
  • 11.8.1. SALES & OPERATING INCOME,
  • 11.8.2. MAJOR PLAYERS R&D EXPENDITURE.

12. COMPANY PROFILES

• 12.1. LONZA GROUP
  • 12.1.1. COMPANY OVERVIEW
  • 12.1.2. FINANCIAL OVERVIEW
  • 12.1.3. PRODUCTS OFFERED
  • 12.1.4. KEY DEVELOPMENTS
  • 12.1.5. SWOT ANALYSIS
  • 12.1.6. KEY STRATEGIES
• 12.2. THERMO FISHER SCIENTIFIC INC.
  • 12.2.1. COMPANY OVERVIEW
  • 12.2.2. FINANCIAL OVERVIEW
  • 12.2.3. PRODUCTS OFFERED
  • 12.2.4. KEY DEVELOPMENTS
  • 12.2.5. SWOT ANALYSIS
  • 12.2.6. KEY STRATEGIES
• 12.3. MERCK KGAA
  • 12.3.1. COMPANY OVERVIEW
  • 12.3.2. FINANCIAL OVERVIEW
  • 12.3.3. PRODUCTS OFFERED
  • 12.3.4. KEY DEVELOPMENTS
  • 12.3.5. SWOT ANALYSIS
  • 12.3.6. KEY STRATEGIES
• 12.4. WUXI APPTEC
  • 12.4.1. COMPANY OVERVIEW
  • 12.4.2. FINANCIAL OVERVIEW
  • 12.4.3. PRODUCTS OFFERED
  • 12.4.4. KEY DEVELOPMENTS
  • 12.4.5. SWOT ANALYSIS
  • 12.4.6. KEY STRATEGIES
• 12.5. CATALENT, INC.
  • 12.5.1. COMPANY OVERVIEW
  • 12.5.2. FINANCIAL OVERVIEW
  • 12.5.3. PRODUCTS OFFERED
  • 12.5.4. KEY DEVELOPMENTS
  • 12.5.5. SWOT ANALYSIS
  • 12.5.6. KEY STRATEGIES
• 12.6. SAMSUNG BIOLOGICS
  • 12.6.1. COMPANY OVERVIEW
  • 12.6.2. FINANCIAL OVERVIEW
  • 12.6.3. PRODUCTS OFFERED
  • 12.6.4. KEY DEVELOPMENTS
  • 12.6.5. SWOT ANALYSIS
  • 12.6.6. KEY STRATEGIES
• 12.7. FUJIFILM DIOSYNTH BIOTECHNOLOGIES
  • 12.7.1. COMPANY OVERVIEW
  • 12.7.2. FINANCIAL OVERVIEW
  • 12.7.3. PRODUCTS OFFERED
  • 12.7.4. KEY DEVELOPMENTS
  • 12.7.5. SWOT ANALYSIS
  • 12.7.6. KEY STRATEGIES
• 12.8. CHARLES RIVER LABORATORIES
  • 12.8.1. COMPANY OVERVIEW
  • 12.8.2. FINANCIAL OVERVIEW
  • 12.8.3. PRODUCTS OFFERED
  • 12.8.4. KEY DEVELOPMENTS
  • 12.8.5. SWOT ANALYSIS
  • 12.8.6. KEY STRATEGIES
• 12.9. CYTIVA
  • 12.9.1. COMPANY OVERVIEW
  • 12.9.2. FINANCIAL OVERVIEW
  • 12.9.3. PRODUCTS OFFERED
  • 12.9.4. KEY DEVELOPMENTS
  • 12.9.5. SWOT ANALYSIS
  • 12.9.6. KEY STRATEGIES
• 12.10. NOVASEP
  • 12.10.1. COMPANY OVERVIEW
  • 12.10.2. FINANCIAL OVERVIEW
  • 12.10.3. PRODUCTS OFFERED
  • 12.10.4. KEY DEVELOPMENTS
  • 12.10.5. SWOT ANALYSIS
  • 12.10.6. KEY STRATEGIES

13. APPENDIX

• 13.1. REFERENCES
• 13.2. RELATED REPORTS